Phase 3 open-label RCT in 530 adults ≥50 years: giving adjuvanted RSVPreF3 with recombinant zoster vaccine on the same day was non-inferior to a month apart for RSV-A/B and anti-gE responses; solicited systemic AEs 73.6% vs 60.4% after visit 1.
RCTn = 530
Roussy et al. Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age